We used the non-ATP competitive inhibitor of MK2 activation, CMPD1, together with the genetic MK2 knock-down and two ATP-competitive MK2 inhibitors MK2i and PF-3644022 to address the question whether MK2 inhibition could be a useful strategy to attenuate growth of glioblastoma tumours. The gene discussed is MAPKAPK2; the disease is glioblastoma.